CTLA4 and melanoma: A study of patients with melanoma brain metastases showed that concurrent immunotherapy with anti-PDL1 and anti-CTLA4 given within 4 weeks of stereotactic radiosurgery led to improved response of brain lesions relative to treatments that were separated by more than 4 weeks (Qian et al., 2016).